Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Chen, Pei Min ^a   Yen, Men Luh ^b   Liu, Ko Jiunn ^c   Sytwu, Huey Kang ^d   Yen, B Linju ^a,e  

^a National Health Research Institutes NHRI   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

bone marrow; dendritic cells; fetal; immunomodulation; major histocompatibility complex (MHC) molecules; mesenchymal stem cells; multilineage differentiation; natural killer lymphocytes; T lymphocytes

Indexed keywords

ADULT; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL INTERACTION; CELL ISOLATION; CELL LINEAGE; CELL PROLIFERATION; DENDRITIC CELL; FETUS; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; ADULT STEM CELL; BIOLOGICAL THERAPY; CYTOLOGY; IMMUNOLOGY; METHODOLOGY;

IMMUNOLOGIC FACTOR;

ADULT STEM CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; FETUS; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELLS; MULTIPOTENT STEM CELLS; T-LYMPHOCYTES; TISSUE THERAPY;

EID: 79960563303     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-49     Document Type: Review

References (158)

1. Multilineage potential of adult human mesenchymal stem cells. Pittenger MF Mackay AM, Beck SC Jaiswal RK, Douglas R Mosca JD, Moorman MA Simonetti DW, Craig S Marshak DR, Science 1999 284 5411 143 147 10.1126/science.284.5411.143 10102814 (Pubitemid 29282067)
2. Marrow stromal cells as stem cells for nonhematopoietic tissues. Prockop DJ, Science 1997 276 5309 71 74 10.1126/science.276.5309.71 9082988 (Pubitemid 27161245)
3. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Friedenstein AJ Petrakova KV, Kurolesova AI Frolova GP, Transplantation 1968 6 2 230 247 10.1097/00007890-196803000-00009 5654088
4. Therapeutic applications of mesenchymal stromal cells. Brooke G Cook M, Blair C Han R, Heazlewood C Jones B, Kambouris M Kollar K, McTaggart S Pelekanos R, et al. Semin Cell Dev Biol 2007 18 6 846 858 10.1016/j.semcdb.2007.09.012 18024097 (Pubitemid 350138458)
5. Multilineage cells from human adipose tissue: implications for cell-based therapies. Zuk PA Zhu M Mizuno H Huang J, Futrell JW Katz AJ, Benhaim P Lorenz HP, Hedrick MH, Tissue Eng 2001 7 2 211 228 10.1089/107632701300062859 11304456 (Pubitemid 32295155)
6. Stem cell characteristics of human trabecular bone-derived cells. Sottile V Halleux C Bassilana F Keller H, Seuwen K, Bone 2002 30 5 699 704 10.1016/S8756-3282(02)00674-9 11996907 (Pubitemid 34467990)
7. Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. Noth U Osyczka AM, Tuli R Hickok NJ, Danielson KG Tuan RS, J Orthop Res 2002 20 5 1060 1069 10.1016/S0736-0266(02)00018-9 12382974
8. Isolation of multipotent cells from human term placenta. Yen BL Huang HI, Chien CC Jui HY, Ko BS Yao M, Shun CT Yen ML, Lee MC Chen YC, Stem Cells 2005 23 1 3 9 10.1634/stemcells.2004-0098 15625118 (Pubitemid 40105287)
9. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Lee OK Kuo TK, Chen WM Lee KD, Hsieh SL Chen TH, Blood 2004 103 5 1669 1675 10.1182/blood-2003-05-1670 14576065 (Pubitemid 38268958)
10. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Tsai MS Lee JL, Chang YJ Hwang SM, Hum Reprod 2004 19 6 1450 1456 10.1093/humrep/deh279 15105397
11. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Wang HS Hung SC Peng ST Huang CC, Wei HM Guo YJ, Fu YS Lai MC, Chen CC, Stem Cells 2004 22 7 1330 1337 10.1634/stemcells.2004-0013 15579650
12. Immunologic properties of human fetal mesenchymal stem cells. Gotherstrom C Ringden O, Tammik C Zetterberg E, Westgren M Le Blanc K, Am J Obstet Gynecol 2004 190 1 239 245 10.1016/j.ajog.2003.07.022 14749666 (Pubitemid 38156354)
13. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Campagnoli C Roberts IA, Kumar S Bennett PR, Bellantuono I Fisk NM, Blood 2001 98 8 2396 2402 10.1182/blood.V98.8.2396 11588036
14. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M Le Blanc K, Mueller I Slaper-Cortenbach I, Marini F Krause D, Deans R Keating A, Prockop D Horwitz E, Cytotherapy 2006 8 4 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
15. The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Picinich SC Mishra PJ Mishra PJ Glod J, Banerjee D, Expert Opin Biol Ther 2007 7 7 965 973 10.1517/14712598.7.7.965 17665987 (Pubitemid 47204355)
16. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. Giordano A Galderisi U Marino IR, J Cell Physiol 2007 211 1 27 35 10.1002/jcp.20959 17226788 (Pubitemid 46363893)
17. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Bartholomew A Sturgeon C, Siatskas M Ferrer K, McIntosh K Patil S, Hardy W Devine S, Ucker D Deans R, et al. Exp Hematol 2002 30 1 42 48 10.1016/S0301-472X(01)00769-X 11823036 (Pubitemid 34059216)
18. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Le Blanc K Tammik C Rosendahl K Zetterberg E, Ringden O, Exp Hematol 2003 31 10 890 896 10.1016/S0301-472X(03) 00110-3 14550804 (Pubitemid 37211373)
19. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Di Nicola M Carlo-Stella C, Magni M Milanesi M, Longoni PD Matteucci P, Grisanti S Gianni AM, Blood 2002 99 10 3838 3843 10.1182/blood.V99.10.3838 11986244
20. Graft-versus-host disease: emerging concepts in prevention and therapy. Dean RM Bishop MR, Curr Hematol Rep 2003 2 4 287 294 12901325
21. Umbilical cord blood transplantation: current practice and future innovations. Barker JN Wagner JE, Crit Rev Oncol Hematol 2003 48 1 35 43 10.1016/S1040-8428(03)00092-1 14585482 (Pubitemid 37336490)
22. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Le Blanc K Frassoni F, Ball L Locatelli F, Roelofs H Lewis I, Lanino E Sundberg B, Bernardo ME Remberger M, et al. Lancet 2008 371 9624 1579 1586 10.1016/S0140-6736(08)60690-X 18468541 (Pubitemid 351626841)
23. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Jurewicz M Yang S, Augello A Godwin JG, Moore RF Azzi J, Fiorina P Atkinson M, Sayegh MH Abdi R, Diabetes 2010 59 12 3139 3147 10.2337/db10-0542 20841611
24. 2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nemeth K Leelahavanichkul A, Yuen PS Mayer B, Parmelee A Doi K, Robey PG Leelahavanichkul K, Koller BH Brown JM, et al. Nat Med 2009 15 1 42 49 10.1038/nm.1905 19098906
25. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Augello A Tasso R Negrini SM Cancedda R, Pennesi G, Arthritis Rheum 2007 56 4 1175 1186 10.1002/art.22511 17393437 (Pubitemid 46608642)
26. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K Rasmusson I Sundberg B Gotherstrom C, Hassan M Uzunel M, Ringden O, Lancet 2004 363 9419 1439 1441 10.1016/S0140-6736(04)16104-7 15121408 (Pubitemid 38586721)
27. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Barry FP Murphy JM, English K Mahon BP, Stem Cells Dev 2005 14 3 252 265 10.1089/scd.2005.14.252 15969620 (Pubitemid 40885249)
28. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. Majumdar MK Keane-Moore M Buyaner D Hardy WB, Moorman MA McIntosh KR, Mosca JD, J Biomed Sci 2003 10 2 228 241 10.1007/BF02256058 12595759 (Pubitemid 36302404)
29. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Tse WT Pendleton JD Beyer WM Egalka MC, Guinan EC, Transplantation 2003 75 3 389 397 10.1097/01.TP.0000045055.63901.A9 12589164 (Pubitemid 36222968)
30. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. Klyushnenkova E Mosca JD, Zernetkina V Majumdar MK, Beggs KJ Simonetti DW, Deans RJ McIntosh KR, J Biomed Sci 2005 12 1 47 57 10.1007/s11373-004-8183-7 15864738 (Pubitemid 40576763)
31. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Stenderup K Justesen J, Clausen C Kassem M, Bone 2003 33 6 919 926 10.1016/j.bone.2003.07.005 14678851 (Pubitemid 37543568)
32. Malignant melanoma. de Braud F Khayat D, Kroon BB Valdagni R, Bruzzi P Cascinelli N, Crit Rev Oncol Hematol 2003 47 1 35 63 10.1016/S1040-8428(02) 00077-X 12853098 (Pubitemid 36805636)
33. Mesenchymal progenitor cells in human umbilical cord blood. Erices A Conget P Minguell JJ, Br J Haematol 2000 109 1 235 242 10.1046/j.1365-2141.2000. 01986.x 10848804 (Pubitemid 30340601)
34. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Sarugaser R Lickorish D Baksh D Hosseini MM, Davies JE, Stem Cells 2005 23 2 220 229 10.1634/stemcells.2004-0166 15671145 (Pubitemid 40239517)
35. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. In 't Anker PS Scherjon SA, Kleijburg-van der Keur C Noort WA, Claas FH Willemze R, Fibbe WE Kanhai HH, Blood 2003 102 4 1548 1549 10.1182/blood-2003-04-1291 12900350 (Pubitemid 36988070)
36. Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. Bachmann MF Kohler G Ecabert B Mak TW, Kopf M, J Immunol 1999 163 3 1128 1131 10415006 (Pubitemid 29352726)
37. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Fukuchi Y Nakajima H, Sugiyama D Hirose I, Kitamura T Tsuji K, Stem Cells 2004 22 5 649 658 10.1634/stemcells.22-5-649 15342929 (Pubitemid 39166923)
38. Mesengenic progenitor cells derived from human placenta. Wulf GG Viereck V Hemmerlein B Haase D, Vehmeyer K Pukrop T, Glass B Emons G, Trumper L, Tissue Eng 2004 10 7-8 1136 1147 10.1089/ten.2004.10.1136 15363170 (Pubitemid 39223792)
39. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. In 't Anker PS Scherjon SA Kleijburg-van der Keur C de Groot-Swings GM, Claas FH Fibbe WE, Kanhai HH, Stem Cells 2004 22 7 1338 1345 10.1634/stemcells.2004-0058 15579651 (Pubitemid 39636409)
40. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Chang CJ Yen ML Chen YC Chien CC, Huang HI Bai CH, Yen BL, Stem Cells 2006 24 11 2466 2477 10.1634/stemcells.2006-0071 17071860 (Pubitemid 44674307)
41. Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. Chiavegato A Bollini S, Pozzobon M Callegari A, Gasparotto L Taiani J, Piccoli M Lenzini E, Gerosa G Vendramin I, et al. J Mol Cell Cardiol 2007 42 4 746 759 10.1016/j.yjmcc.2006.12.008 17300799 (Pubitemid 46533977)
42. Human umbilical cord blood-derived stromal cells suppress xenogeneic immune cell response in vitro. Hao L Zhang C, Chen XH Zou ZM, Zhang X Kong PY, Liang X Gao L, Peng XG Sun AH, et al. Croat Med J 2009 50 4 351 360 10.3325/cmj.2009.50.351 19673035
43. Stem cells derived from human fetal membranes display multilineage differentiation potential. Ilancheran S Michalska A, Peh G Wallace EM, Pera M Manuelpillai U, Biol Reprod 2007 77 3 577 588 10.1095/biolreprod.106.055244 17494917 (Pubitemid 47328622)
44. Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Kim J Lee Y Kim H Hwang KJ, Kwon HC Kim SK, Cho DJ Kang SG, You J, Cell Prolif 2007 40 1 75 90 17227297 (Pubitemid 46103692)
45. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Lu LL Liu YJ, Yang SG Zhao QJ, Wang X Gong W, Han ZB Xu ZS, Lu YX Liu D, et al. Haematologica 2006 91 8 1017 1026 16870554
46. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. Oh W Kim DS, Yang YS Lee JK, Cell Immunol 2008 251 2 116 123 10.1016/j.cellimm.2008.04.003 18495100
47. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Portmann-Lanz CB Schoeberlein A Huber A Sager R, Malek A Holzgreve W, Surbek DV, Am J Obstet Gynecol 2006 194 3 664 673 10.1016/j.ajog.2006.01.101 16522395 (Pubitemid 43333137)
48. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Roubelakis MG Pappa KI, Bitsika V Zagoura D, Vlahou A Papadaki HA, Antsaklis A Anagnou NP, Stem Cells Dev 2007 16 6 931 952 10.1089/scd.2007.0036 18047393
49. Inducing proliferation of human amniotic epithelial (HAE) cells for cell therapy. Terada S Matsuura K Enosawa S Miki M, Hoshika A Suzuki S, Sakuragawa N, Cell Transplant 2000 9 5 701 704 11144969 (Pubitemid 32002579)
50. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Wang M Yang Y Yang D Luo F, Liang W Guo S, Xu J, Immunology 2009 126 2 220 232 10.1111/j.1365-2567.2008.02891.x 18624725
51. Immune properties of human umbilical cord Wharton's jelly-derived cells. Weiss ML Anderson C, Medicetty S Seshareddy KB, Weiss RJ VanderWerff I, Troyer D McIntosh KR, Stem Cells 2008 26 11 2865 2874 10.1634/stemcells.2007-1028 18703664
52. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Weiss ML Medicetty S, Bledsoe AR Rachakatla RS, Choi M Merchav S, Luo Y Rao MS, Velagaleti G Troyer D, Stem Cells 2006 24 3 781 792 10.1634/stemcells.2005-0330 16223852 (Pubitemid 44464783)
53. Human-placenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Li C Zhang W, Jiang X Mao N, Cell Tissue Res 2007 330 3 437 446 10.1007/s00441-007-0504-5 17899199 (Pubitemid 350098216)
54. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Wolbank S Peterbauer A, Fahrner M Hennerbichler S, van Griensven M Stadler G, Redl H Gabriel C, Tissue Eng 2007 13 6 1173 1183 10.1089/ten.2006.0313 17518752 (Pubitemid 46986718)
55. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Magatti M De Munari S, Vertua E Gibelli L, Wengler GS Parolini O, Stem Cells 2008 26 1 182 192 10.1634/stemcells.2007-0491 17901399
56. Engraftment potential of human amnion and chorion cells derived from term placenta. Bailo M Soncini M, Vertua E Signoroni PB, Sanzone S Lombardi G, Arienti D Calamani F, Zatti D Paul P, et al. Transplantation 2004 78 10 1439 1448 10.1097/01.TP.0000144606.84234.49 15599307 (Pubitemid 39552929)
57. Immunosuppressive factors secreted by human amniotic epithelial cells. Li H Niederkorn JY Neelam S Mayhew E, Word RA McCulley JP, Alizadeh H, Invest Ophthalmol Vis Sci 2005 46 3 900 907 10.1167/iovs.04-0495 15728546 (Pubitemid 41321026)
58. Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S Pittenger MF, Blood 2005 105 4 1815 1822 10.1182/blood-2004-04-1559 15494428 (Pubitemid 40223708)
59. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Krampera M Cosmi L, Angeli R Pasini A, Liotta F Andreini A, Santarlasci V Mazzinghi B, Pizzolo G Vinante F, et al. Stem Cells 2006 24 2 386 398 10.1634/stemcells.2005-0008 16123384 (Pubitemid 44464808)
60. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Krampera M Glennie S Dyson J Scott D, Laylor R Simpson E, Dazzi F, Blood 2003 101 9 3722 3729 10.1182/blood-2002-07-2104 12506037 (Pubitemid 36857965)
61. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Glennie S Soeiro I Dyson PJ Lam EW, Dazzi F, Blood 2005 105 7 2821 2827 10.1182/blood-2004-09-3696 15591115 (Pubitemid 40446275)
62. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Benvenuto F Ferrari S, Gerdoni E Gualandi F, Frassoni F Pistoia V, Mancardi G Uccelli A, Stem Cells 2007 25 7 1753 1760 10.1634/stemcells.2007-0068 17395776 (Pubitemid 47121854)
63. + T cell lineage differentiation. Zhou L Chong MM Littman DR, Immunity 2009 30 5 646 655 10.1016/j.immuni.2009.05.001 19464987
64. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Bai L Lennon DP Eaton V Maier K, Caplan AI Miller SD, Miller RH, Glia 2009 57 11 1192 1203 10.1002/glia.20841 19191336
65. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. Rafei M Campeau PM, Aguilar-Mahecha A Buchanan M, Williams P Birman E, Yuan S Young YK, Boivin MN Forner K, et al. J Immunol 2009 182 10 5994 6002 10.4049/jimmunol.0803962 19414750
66. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Ghannam S Pene J Torcy-Moquet G Jorgensen C, Yssel H, J Immunol 2010 185 1 302 312 10.4049/jimmunol.0902007 20511548
67. + T-cell subsets expressing a regulatory/suppressive phenotype. Maccario R Podesta M, Moretta A Cometa A, Comoli P Montagna D, Daudt L Ibatici A, Piaggio G Pozzi S, et al. Haematologica 2005 90 4 516 525 15820948 (Pubitemid 40592895)
68. Human T regulatory cell therapy: take a billion or so and call me in the morning. Riley JL June CH Blazar BR, Immunity 2009 30 5 656 665 10.1016/j.immuni.2009.04.006 19464988
69. + T regulatory cell-mediated suppression. Shevach EM, Immunity 2009 30 5 636 645 10.1016/j.immuni.2009.04.010 19464986
70. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. Itoh M Takahashi T Sakaguchi N Kuniyasu Y, Shimizu J Otsuka F, Sakaguchi S, J Immunol 1999 162 9 5317 5326 10228007 (Pubitemid 29307138)
71. + regulatory T cells. English K Ryan JM, Tobin L Murphy MJ, Barry FP Mahon BP, Clin Exp Immunol 2009 156 1 149 160 10.1111/j.1365-2249.2009.03874.x 19210524
72. + regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Prevosto C Zancolli M Canevali P Zocchi MR, Poggi A, Haematologica 2007 92 7 881 888 10.3324/haematol.11240 17606437 (Pubitemid 350144234)
73. Mesenchymal cells recruit and regulate T regulatory cells. Di Ianni M Del Papa B De Ioanni M Moretti L, Bonifacio E Cecchini D, Sportoletti P Falzetti F, Tabilio A, Exp Hematol 2008 36 3 309 318 10.1016/j.exphem.2007.11.007 18279718 (Pubitemid 351221170)
74. + regulatory T cells. Selmani Z Naji A, Zidi I Favier B, Gaiffe E Obert L, Borg C Saas P, Tiberghien P Rouas-Freiss N, et al. Stem Cells 2008 26 1 212 222 10.1634/stemcells.2007-0554 17932417
75. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Batten P Sarathchandra P Antoniw JW Tay SS, Lowdell MW Taylor PM, Yacoub MH, Tissue Eng 2006 12 8 2263 2273 10.1089/ten.2006.12.2263 16968166 (Pubitemid 44734984)
76. Immune modulation by mesenchymal stem cells. Rasmusson I, Exp Cell Res 2006 312 12 2169 2179 10.1016/j.yexcr.2006.03.019 16631737 (Pubitemid 43928946)
77. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Groh ME Maitra B, Szekely E Koc ON, Exp Hematol 2005 33 8 928 934 10.1016/j.exphem.2005.05.002 16038786 (Pubitemid 40982660)
78. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Rasmusson I Ringden O, Sundberg B Le Blanc K, Exp Cell Res 2005 305 1 33 41 10.1016/j.yexcr.2004.12.013 15777785 (Pubitemid 40380651)
79. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Ryan JM Barry F, Murphy JM Mahon BP, Clin Exp Immunol 2007 149 2 353 363 10.1111/j.1365-2249.2007.03422.x 17521318 (Pubitemid 47063057)
80. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Meisel R Zibert A, Laryea M Gobel U, Daubener W Dilloo D, Blood 2004 103 12 4619 4621 10.1182/blood-2003-11-3909 15001472 (Pubitemid 38745993)
81. Mesenchymal stem cells induce apoptosis of activated T cells. Plumas J Chaperot L, Richard MJ Molens JP, Bensa JC Favrot MC, Leukemia 2005 19 9 1597 1604 10.1038/sj.leu.2403871 16049516 (Pubitemid 43090404)
82. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Chabannes D Hill M, Merieau E Rossignol J, Brion R Soulillou JP, Anegon I Cuturi MC, Blood 2007 110 10 3691 3694 10.1182/blood-2007-02-075481 17684157 (Pubitemid 350159638)
83. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Nasef A Mazurier C, Bouchet S Francois S, Chapel A Thierry D, Gorin NC Fouillard L, Cell Immunol 2008 253 1-2 16 22 10.1016/j.cellimm.2008. 06.002 18639869
84. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Gieseke F Schutt B Viebahn S Koscielniak E, Friedrich W Handgretinger R, Muller I, Blood 2007 110 6 2197 2200 10.1182/blood-2007-04-083162 17522338 (Pubitemid 47443941)
85. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Nasef A Mathieu N, Chapel A Frick J, Francois S Mazurier C, Boutarfa A Bouchet S, Gorin NC Thierry D, et al. Transplantation 2007 84 2 231 237 10.1097/01.tp.0000267918.07906.08 17667815 (Pubitemid 47205757)
86. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Gieseke F Bohringer J, Bussolari R Dominici M, Handgretinger R Muller I, Blood 2010 116 19 3770 3779 10.1182/blood-2010-02- 270777 20644118
87. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Sioud M Mobergslien A, Boudabous A Floisand Y, Int J Oncol 2011 38 2 385 390 21165555
88. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Liotta F Angeli R, Cosmi L Fili L, Manuelli C Frosali F, Mazzinghi B Maggi L, Pasini A Lisi V, et al. Stem Cells 2008 26 1 279 289 10.1634/stemcells.2007-0454 17962701
89. + monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells. Wang D Chen K, Du WT Han ZB, Ren H Chi Y, Yang SG Bayard F, Zhu D Han ZC, Exp Cell Res 2010 316 15 2414 2423 10.1016/j.yexcr.2010.04.018 20420825
90. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. Cutler AJ Limbani V, Girdlestone J Navarrete CV, J Immunol 2010 185 11 6617 6623 10.4049/jimmunol.1002239 20980628
91. 2-dependent mechanism. Chen K Wang D, Du WT Han ZB, Ren H Chi Y, Yang SG Zhu D, Bayard F Han ZC, Clin Immunol 2010 135 3 448 458 10.1016/j.clim.2010.01.015 20207200
92. Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions. Girdlestone J Limbani VA, Cutler AJ Navarrete CV, Cytotherapy 2009 11 6 738 748 10.3109/14653240903079401 19878060
93. + cells. Zhang Y Li C, Jiang X Zhang S, Wu Y Liu B, Tang P Mao N, Exp Hematol 2004 32 7 657 664 10.1016/j.exphem.2004.04.001 15246162 (Pubitemid 38891535)
94. Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Roelen DL van der Mast BJ, in't Anker PS Kleijburg C, Eikmans M van Beelen E, de Groot-Swings GM Fibbe WE, Kanhai HH Scherjon SA, et al. Hum Immunol 2009 70 1 16 23 10.1016/j.humimm.2008.10.016 19010366
95. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. Prasanna SJ Gopalakrishnan D, Shankar SR Vasandan AB, PLoS One 2010 5 2 9016. 20126406
96. MHC class II proteins and disease: a structural perspective. Jones EY Fugger L, Strominger JL Siebold C, Nat Rev Immunol 2006 6 4 271 282 10.1038/nri1805 16557259
97. Dendritic cells in the T-cell areas of lymphoid organs. Steinman RM Pack M Inaba K, Immunol Rev 1997 156 25 37 10.1111/j.1600-065X.1997.tb00956.x 9176697 (Pubitemid 27197190)
98. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Jiang XX Zhang Y Liu B Zhang SX, Wu Y Yu XD, Mao N, Blood 2005 105 10 4120 4126 10.1182/blood-2004-02-0586 15692068 (Pubitemid 40656164)
99. 2. Spaggiari GM Abdelrazik H, Becchetti F Moretta L, Blood 2009 113 26 6576 6583 10.1182/blood-2009-02-203943 19398717
100. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Beyth S Borovsky Z, Mevorach D Liebergall M, Gazit Z Aslan H, Galun E Rachmilewitz J, Blood 2005 105 5 2214 2219 10.1182/blood-2004-07-2921 15514012 (Pubitemid 40731815)
101. + hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. Li YP Paczesny S, Lauret E Poirault S, Bordigoni P Mekhloufi F, Hequet O Bertrand Y, Ou-Yang JP Stoltz JF, et al. J Immunol 2008 180 3 1598 1608 18209056
102. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Chan WK Lau AS, Li JC Law HK, Lau YL Chan GC, Exp Hematol 2008 36 11 1545 1555 10.1016/j.exphem.2008.06.008 18715686
103. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Stagg J Pommey S, Eliopoulos N Galipeau J, Blood 2006 107 6 2570 2577 10.1182/blood-2005-07-2793 16293599 (Pubitemid 43348704)
104. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Chan JL Tang KC Patel AP Bonilla LM, Pierobon N Ponzio NM, Rameshwar P, Blood 2006 107 12 4817 4824 10.1182/blood-2006-01-0057 16493000 (Pubitemid 43882633)
105. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Francois M Romieu-Mourez R, Stock-Martineau S Boivin MN, Bramson JL Galipeau J, Blood 2009 114 13 2632 2638 19654411
106. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Morandi F Raffaghello L Bianchi G Meloni F, Salis A Millo E, Ferrone S Barnaba V, Pistoia V, Stem Cells 2008 26 5 1275 1287 10.1634/stemcells.2007-0878 18292209
107. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. Romieu-Mourez R Francois M, Boivin MN Bouchentouf M, Spaner DE Galipeau J, J Immunol 2009 182 12 7963 7973 10.4049/jimmunol.0803864 19494321
108. Toll-like receptors and their ligands control mesenchymal stem cell functions. Pevsner-Fischer M Morad V, Cohen-Sfady M Rousso-Noori L, Zanin-Zhorov A Cohen S, Cohen IR Zipori D, Blood 2007 109 4 1422 1432 10.1182/blood-2006-06- 028704 17038530 (Pubitemid 46239573)
109. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Tomchuck SL Zwezdaryk KJ, Coffelt SB Waterman RS, Danka ES Scandurro AB, Stem Cells 2008 26 1 99 107 10.1634/stemcells.2007- 0563 17916800
110. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Opitz CA Litzenburger UM, Lutz C Lanz TV, Tritschler I Koppel A, Tolosa E Hoberg M, Anderl J Aicher WK, et al. Stem Cells 2009 27 4 909 919 10.1002/stem.7 19353519
111. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Kern S Eichler H Stoeve J Kluter H, Bieback K, Stem Cells 2006 24 5 1294 1301 10.1634/stemcells.2005-0342 16410387 (Pubitemid 44464698)
112. Isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Parolini O Alviano F, Bagnara GP Bilic G, Buhring HJ Evangelista M, Hennerbichler S Liu B, Magatti M Mao N, et al. Stem Cells 2008 26 2 300 311 10.1634/stemcells.2007-0594 17975221 (Pubitemid 351413589)
113. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Magatti M De Munari S Vertua E Nassauto C, Albertini A Wengler GS, Parolini O, Cell Transplant 2009 18 8 899 914 10.3727/096368909X471314 19523334
114. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Kronsteiner B Peterbauer-Scherb A Grillari-Voglauer R Redl H, Gabriel C van Griensven M, Wolbank S, Cell Immunol 2011 267 1 30 38 10.1016/j.cellimm.2010.11.001 21145536
115. Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin-12 production by mature dendritic cells. van den Berk LC Roelofs H, Huijs T Siebers-Vermeulen KG, Raymakers RA Kogler G, Figdor CG Torensma R, Immunology 2009 128 4 564 572 10.1111/j.1365-2567.2009.03142.x 19930046
116. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Moretta A Locatelli F Moretta L, Immunol Rev 2008 224 58 69 10.1111/j.1600-065X.2008.00651.x 18759920
117. Human natural killer cells. Caligiuri MA, Blood 2008 112 3 461 469 10.1182/blood-2007-09-077438 18650461
118. Interactions between human mesenchymal stem cells and natural killer cells. Sotiropoulou PA Perez SA Gritzapis AD Baxevanis CN, Papamichail M, Stem Cells 2006 24 1 74 85 10.1634/stemcells.2004-0359 16099998
119. 2. Spaggiari GM Capobianco A, Abdelrazik H Becchetti F, Mingari MC Moretta L, Blood 2008 111 3 1327 1333 17951526 (Pubitemid 351213419)
120. Antigen presenting cells and stromal cells trigger human natural killer lymphocytes to autoreactivity: evidence for the involvement of natural cytotoxicity receptors (NCR) and NKG2D. Poggi A Zocchi MR, Clin Dev Immunol 2006 13 2-4 325 336 10.1080/17402520600578194 17162374 (Pubitemid 44950048)
121. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Spaggiari GM Capobianco A Becchetti S Mingari MC, Moretta L, Blood 2006 107 4 1484 1490 10.1182/blood-2005-07-2775 16239427 (Pubitemid 43242385)
122. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Rouas-Freiss N Goncalves RM Menier C Dausset J, Carosella ED, Proc Natl Acad Sci USA 1997 94 21 11520 11525 10.1073/pnas.94.21.11520 9326642 (Pubitemid 27451031)
123. A critical look at HLA-G. Apps R Gardner L Moffett A, Trends Immunol 2008 29 7 313 321 10.1016/j.it.2008.02.012 18538632
124. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Carosella ED Favier B Rouas-Freiss N Moreau P, Lemaoult J, Blood 2008 111 10 4862 4870 10.1182/blood-2007-12-127662 18334671
125. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. LeMaoult J Zafaranloo K, Le Danff C Carosella ED, FASEB J 2005 19 6 662 664 15670976 (Pubitemid 40471278)
126. + mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. La Rocca G Anzalone R, Corrao S Magno F, Loria T Lo Iacono M, Di Stefano A Giannuzzi P, Marasa L Cappello F, et al. Histochem Cell Biol 2009 131 2 267 282 10.1007/s00418-008-0519-3 18836737
127. Surface expression of HLA-G is involved in mediating immunomodulatory effects of placenta-derived multipotent cells (PDMCs) towards natural killer lymphocytes. Liu KJ Wang JC Chang CJ Hu HI, Hsu PJ Wu YC, Bai CH Sytwu HK, Yen BL, Cell Transplant 2011
128. Immunological tolerance of the human fetus. Gaunt G Ramin K, Am J Perinatol 2001 18 6 299 312 10.1055/s-2001-17861 11607848 (Pubitemid 33000736)
129. Natural killer cells and pregnancy. Moffett-King A, Nat Rev Immunol 2002 2 9 656 663 10.1038/nri886 12209134 (Pubitemid 37328723)
130. How I treat refractory acute GVHD. Deeg HJ, Blood 2007 109 10 4119 4126 10.1182/blood-2006-12-041889 17234737 (Pubitemid 46743372)
131. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Aksu AE Horibe E, Sacks J Ikeguchi R, Breitinger J Scozio M, Unadkat J Feili-Hariri M, Clin Immunol 2008 127 3 348 358 10.1016/j.clim.2008.02.003 18387852
132. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Zhou HP Yi DH Yu SQ Sun GC, Cui Q Zhu HL, Liu JC Zhang JZ, Wu TJ, Transplant Proc 2006 38 9 3046 3051 10.1016/j.transproceed. 2006.10.002 17112896 (Pubitemid 44737988)
133. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Yanez R Lamana ML, Garcia-Castro J Colmenero I, Ramirez M Bueren JA, Stem Cells 2006 24 11 2582 2591 10.1634/stemcells.2006-0228 16873762 (Pubitemid 44674320)
134. Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Kim DW Chung YJ Kim TG Kim YL, Oh IH, Blood 2004 103 5 1941 1948 10.1182/blood-2003-05-1601 14592834
135. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Ge W Jiang J Baroja ML Arp J, Zassoko R Liu W, Bartholomew A Garcia B, Wang H, Am J Transplant 2009 9 8 1760 1772 10.1111/j.1600-6143.2009.02721.x 19563344
136. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Popp FC Eggenhofer E, Renner P Slowik P, Lang SA Kaspar H, Geissler EK Piso P, Schlitt HJ Dahlke MH, Transpl Immunol 2008 20 1-2 55 60 10.1016/j.trim.2008.08.004 18762258
137. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. von Bonin M Stolzel F, Goedecke A Richter K, Wuschek N Holig K, Platzbecker U Illmer T, Schaich M Schetelig J, et al. Bone Marrow Transplant 2009 43 3 245 251 10.1038/bmt.2008.316 18820709
138. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Fang B Song Y Liao L Zhang Y, Zhao RC, Transplant Proc 2007 39 10 3358 3362 10.1016/j.transproceed. 2007.08.103 18089385 (Pubitemid 350251475)
139. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Muller I Kordowich S Holzwarth C Isensee G, Lang P Neunhoeffer F, Dominici M Greil J, Handgretinger R, Blood Cells Mol Dis 2008 40 1 25 32 10.1016/j.bcmd.2007.06.021 17869550 (Pubitemid 350199635)
140. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Lazarus HM Koc ON, Devine SM Curtin P, Maziarz RT Holland HK, Shpall EJ McCarthy P, Atkinson K Cooper BW, et al. Biol Blood Marrow Transplant 2005 11 5 389 398 10.1016/j.bbmt.2005.02.001 15846293 (Pubitemid 40542932)
141. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Ning H Yang F, Jiang M Hu L, Feng K Zhang J, Yu Z Li B, Xu C Li Y, et al. Leukemia 2008 22 3 593 599 10.1038/sj.leu.2405090 18185520 (Pubitemid 351386730)
142. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Taupin P, Curr Opin Investig Drugs 2006 7 5 473 481 16729725 (Pubitemid 43772988)
143. Mesenchymal stem cells for graft-versus-host disease: a double edged sword? Vianello F Dazzi F, Leukemia 2008 22 3 463 465 10.1038/leu.2008.25 18335000 (Pubitemid 351386715)
144. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Sundin M Ringden O, Sundberg B Nava S, Gotherstrom C Le Blanc K, Haematologica 2007 92 9 1208 1215 10.3324/haematol. 11446 17666368 (Pubitemid 350144179)
145. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Le Blanc K Ringden O, Biol Blood Marrow Transplant 2005 11 5 321 334 10.1016/j.bbmt.2005.01.005 15846285 (Pubitemid 40542924)
146. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Eliopoulos N Stagg J Lejeune L Pommey S, Galipeau J, Blood 2005 106 13 4057 4065 10.1182/blood-2005-03-1004 16118325 (Pubitemid 41775910)
147. + human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Bensidhoum M Chapel A, Francois S Demarquay C, Mazurier C Fouillard L, Bouchet S Bertho JM, Gourmelon P Aigueperse J, et al. Blood 2004 103 9 3313 3319 10.1182/blood-2003-04-1121 14715641 (Pubitemid 38525658)
148. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Ball LM Bernardo ME, Roelofs H Lankester A, Cometa A Egeler RM, Locatelli F Fibbe WE, Blood 2007 110 7 2764 2767 10.1182/blood-2007-04-087056 17638847 (Pubitemid 47523204)
149. Reply to 'The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rates in hematologic malignancy patients: outcome of a pilot clinical study'. Behre G Theurich S, Weber T Christopeit M, Leukemia, Ning, et al, 2009 23 1 178 author reply 179-180 10.1038/leu.2008.150 18548101
150. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Le Blanc K Samuelsson H, Gustafsson B Remberger M, Sundberg B Arvidson J, Ljungman P Lonnies H, Nava S Ringden O, Leukemia 2007 21 8 1733 1738 10.1038/sj.leu.2404777 17541394 (Pubitemid 47086763)
151. + cells in NOD/SCID mice. in 't Anker PS Noort WA, Kruisselbrink AB Scherjon SA, Beekhuizen W Willemze R, Kanhai HH Fibbe WE, Exp Hematol 2003 31 10 881 889 10.1016/S0301-472X(03)00202-9 14550803 (Pubitemid 37211372)
152. Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. Ringden O Remberger M, Svahn BM Barkholt L, Mattsson J Aschan J, Le Blanc K Gustafsson B, Hassan Z Omazic B, et al. Transplantation 2006 81 5 718 725 10.1097/01.tp.0000181457.43146.36 16534474
153. Transplantation of human amniotic cells exerts neuroprotection in MPTP-induced Parkinson disease mice. Kong XY Cai Z, Pan L Zhang L, Shu J Dong YL, Yang N Li Q, Huang XJ Zuo PP, Brain Res 2008 1205 108 115 18353283
154. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Zhao P Ise H, Hongo M Ota M, Konishi I Nikaido T, Transplantation 2005 79 5 528 535 10.1097/01.TP.0000149503.92433.39 15753841 (Pubitemid 40365880)
155. Immunogenicity of human amniotic membrane in experimental xenotransplantation. Kubo M Sonoda Y, Muramatsu R Usui M, Invest Ophthalmol Vis Sci 2001 42 7 1539 1546 11381058 (Pubitemid 32520745)
156. Amniotic stem cells for cellular cardiomyoplasty: promises and premises. Walther G Gekas J Bertrand OF, Catheter Cardiovasc Interv 2009 73 7 917 924 10.1002/ccd.22016 19455667
157. Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood. Prather WR Toren A Meiron M, Expert Opin Biol Ther 2008 8 8 1241 1250 10.1517/14712598.8.8.1241 18613774
158. Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient mice. Hiwase SD Dyson PG, To LB Lewis ID, Stem Cells 2009 27 9 2293 2300 10.1002/stem.157 19544531